Interleukin-1β Disruption Protects Male Mice From Heart Failure With Preserved Ejection Fraction Pathogenesis

Balaji K Srinivas1, Aya Bourdi1, Jacob D O'Regan1

  • 1Department of Physiological Sciences EVMS Norfolk VA USA.

Insights

Interleukin-1β drives heart failure with preserved ejection fraction (HFpEF) by promoting inflammation and endoplasmic reticulum stress. Genetic deletion of interleukin-1β protected against HFpEF development in mice.

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Molecular Biology

Background:

  • Heart failure with preserved ejection fraction (HFpEF) is a complex cardiovascular disease with limited treatment options.
  • The specific role of interleukin-1β (IL-1β) in HFpEF pathogenesis remains unclear.
  • Understanding IL-1β's mechanisms is crucial for developing targeted therapies for HFpEF.

Purpose of the Study:

  • To investigate the role and mechanism of interleukin-1β in the development of heart failure with preserved ejection fraction (HFpEF).
  • To determine if genetic disruption of interleukin-1β can prevent HFpEF pathogenesis.

Main Methods:

  • Utilized C57/Bl6J and interleukin-1β knockout (IL-1β-/-) male mice.
  • Administered a high-fat diet combined with an endothelial nitric oxide synthase inhibitor to induce HFpEF.
  • Assessed various physiological and molecular parameters, including cardiac function, inflammation, and endoplasmic reticulum stress.

Main Results:

  • Mice on the high-fat diet and inhibitor developed HFpEF characteristics: obesity, diabetes, hypertension, cardiac hypertrophy, and endothelial dysfunction.
  • Genetic deletion of interleukin-1β significantly protected mice from developing HFpEF.
  • IL-1β deficiency modulated inflammation and endoplasmic reticulum stress pathways, mitigating HFpEF development.

Conclusions:

  • Interleukin-1β acts as a critical driver in HFpEF pathogenesis.
  • Modulation of inflammation and endoplasmic reticulum stress by IL-1β is a key mechanism in HFpEF.
  • IL-1β represents a potential therapeutic target for treating heart failure with preserved ejection fraction.